Veerhealth Care Ltd. (NIYATILEAS) — Tipsheet

Veerhealth Care lands second ₹1.11 cr order from pharmacy chain

Tipsheet Editorial — Mon, 13 Jul 2026 14:55:51 GMT

Repeat order for hair and oral care products confirms deepening ties with nationwide healthcare network; execution within 45 days.

What’s new

Repeat order worth ₹1.11 cr from the same nationwide pharmacy chain as the July 11 contract.
Order covers hair care and oral care products; execution window of 45 days.
Company reiterates FY27/FY28 guidance and confirms conclusion of preferential warrant allotment.

Why it matters

A second order from the same large client, even at the same value, signals the relationship is extending beyond a one-off trial. For a company with ₹61 cr market cap and thin profitability, consistent revenue from a national chain provides a visible near-term fillip, though at 3.4% of annual revenue the absolute size remains modest.

What we’re watching

Whether order frequency or size increases in subsequent quarters.
Any disclosure of the client name when confidentiality expires.
Impact of the ₹20.25 cr warrant proceeds on working capital and execution capacity.

The full read

Veerhealth Care has followed up its ₹1.11 crore first order from a nationwide pharmacy chain with a second order of identical value. The repeat contract for hair care and oral care products, to be executed within 45 days, confirms that the relationship is moving beyond a trial. The order represents 3.4% of annual revenue, comfortably exceeding nano-cap materiality thresholds. Small. But it provides near-term cash flow visibility. The company also wrapped up its ₹20.25 crore preferential warrant issue and reiterated its forward guidance. For a micro-cap with ₹61 crore market cap and a trailing P/E of 112, consistency from a national client is more valuable than size.

Primary source: BSE · NSE

Veerhealth Care lands ₹1.11 cr order from pharmacy chain, opens new channel

Tipsheet Editorial — Sat, 11 Jul 2026 16:33:59 GMT

Veerhealth Care won a ₹1.11 crore order for haircare and oral care products from a large domestic pharmacy chain, marking its entry into the healthcare distribution channel alongside its existing FMCG contract manufacturing business.

What’s new

Veerhealth Care received a ₹1.11 crore order for haircare and oral care products from a large domestic pharmacy chain.
The order is to be executed within 45 days; client identity is confidential.
This marks the company's entry into a new distribution channel in healthcare, diversifying from its FMCG-focused contract manufacturing.

Why it matters

Though modest at just 3.4% of annual revenue, the order opens a new distribution channel and reduces reliance on FMCG clients. It also follows a ₹3.6 crore face-care order in June, suggesting growing commercial traction. For a company with a ₹61 crore market cap and thin profitability, every incremental revenue source helps.

What we’re watching

Whether more healthcare-distribution orders follow, confirming a new revenue stream.
Execution: the 45-day timeline is tight; any delays could strain credibility.
Profitability of this channel vs. existing FMCG business — margins aren't disclosed.

The full read

Veerhealth Care has bagged a ₹1.11 crore order to supply haircare and oral care products to a large domestic pharmacy chain — a new customer segment and distribution channel for a company that has mostly served FMCG clients. The order, while modest at 3.4% of FY26 revenue of ₹32.48 crore, is to be executed within 45 days, providing near-term cash flow. This is Veerhealth's second supply order in just over a month, following a ₹3.6 crore face-care order in June. For a company with a ₹61 crore market cap, thin profitability (near-zero net profit in the March quarter), and a recent 31% equity dilution from a ₹20.25 crore warrant issue, every incremental revenue stream matters. The undisclosed client and new channel add a layer of diversification that could reduce dependence on any single segment. The open question: whether this is a one-off or the start of a repeatable healthcare-distribution revenue line.

Primary source: BSE · NSE

Veerhealth Care dilutes 31% of equity with ₹20.25 cr warrant issue

Tipsheet Editorial — Thu, 02 Jul 2026 16:35:36 GMT

Promoter entities take 55% of 1 crore fully convertible warrants; capital raise equals nearly a third of market cap

What’s new

Veerhealth Care's committee allotted 1 crore fully convertible warrants at ₹20.25 each, raising ₹20.25 crore.
Promoter-group entities took 55% of the warrants; three non-promoters the remaining 45%.
The raise represents ~31% of the company's ₹61 crore market capitalisation.

Why it matters

For a nano-cap with trailing ROE of 1.8% and a recent loss in Q4 FY26, a dilution of nearly a third of equity is a stark bet on growth. Promoter participation signals confidence, but the scale of dilution raises governance questions and puts pressure on management to deploy the capital profitably.

What we’re watching

Conversion timeline and pricing terms of the warrants.
Disclosure on planned use of the ₹20.25 crore proceeds.
Any follow-on earnings impact as dilution hits EPS.

The full read

Veerhealth Care has approved a preferential issue of 1 crore fully convertible warrants at ₹20.25 each, raising ₹20.25 crore. That sum equals 31% of its ₹61 crore market cap. Promoter entities including Ruchi Yogesh Shah, Shruti Akash Shah, and Yogesh Mahasuklal Shah took 55% of the issue. Three non-promoter individuals took the rest. For a company with ₹17 crore in quarterly sales, 1.8% ROE, and a recent slip to a loss, this is a bold capital event. The dilution is substantial: current equity will expand by 31% if all warrants convert, which will pressure per-share metrics unless the funds are deployed into high-return projects. Promoter participation suggests their conviction. But the size of the raise - nearly a third of market value - demands scrutiny on deployment plans.

Primary source: BSE · NSE

Veerhealth lands ₹3.6 cr face-care order from undisclosed FMCG client

Tipsheet Editorial — Tue, 09 Jun 2026 16:08:12 GMT

The contract is worth 11% of the nano-cap's annual revenue and must ship within 45 days.

What’s new

Veerhealth Care won a ₹3.6 crore order from an unnamed Indian FMCG company for face care products.
Execution is locked in within 45 days.
The deal follows a string of recent wins, including a ₹6.16 crore domestic contract, that lifted annual revenue to ₹32.5 crore in FY26.

Why it matters

For a ₹48 crore market-cap company, a single order of this size is 11% of last year's revenue and 7.5% of the equity value. It's a big chunk of near-term sales packed into a 45-day window. The unnamed FMCG counterparty suggests the client wants discretion, which often means a large brand testing a new contract manufacturer.

What we’re watching

Whether the FY27 revenue run-rate sustains the ₹32.5 cr trajectory from FY26.
If Veerhealth can name the FMCG client once the contract matures.
Gross-margin impact from a large, short-timeline order.

The full read

Veerhealth Care has won a ₹3.6 crore order from an unnamed Indian FMCG company for face care products, to be executed within 45 days. For a contract manufacturer with a ₹48 crore market cap and ₹32.5 crore in FY26 revenue, that single order represents 11% of annual sales and 7.5% of equity value. The deal adds to a recent string of wins, including a ₹6.16 crore domestic contract, that have stretched Veerhealth's order book. The client's identity is locked behind a confidentiality clause, a common move when a large brand is piloting a new manufacturing partner. The revenue is booked fast. The test is whether Veerhealth can keep filling the pipeline at this pace.

Primary source: BSE · NSE

Veerhealth Care revenue nearly doubles to ₹32.5 cr, but Q4 slips to a loss

Tipsheet Editorial — Sat, 30 May 2026 13:05:26 GMT

A one-off ₹31 lakh charge turned the final quarter negative. For the full year, profit rose 39% on a 93% revenue jump.

What’s new

Annual revenue nearly doubled to ₹32.48 crores, up 93% from ₹16.87 crores.
Q4 revenue of ₹16.76 crores was triple the year-ago quarter, but a ₹31 lakh exceptional charge pushed it to a net loss of ₹35.37 lakhs.
Full-year net profit rose 39% to ₹54.40 lakhs; board skipped the dividend to conserve resources.

Why it matters

The results confirm the order wins from the past year are converting to revenue. The catch: profit margins remain paper-thin, and a single ₹31 lakh charge was enough to wipe out the entire final quarter. The no-dividend call is pragmatic for a nano-cap still burning cash on growth.

What we’re watching

Whether Q4's revenue momentum is sustained into the new fiscal year.
How quickly the company can improve profitability as scale increases.
The timing and size of the next dividend, if any.

The full read

Veerhealth Care's FY26 numbers tell a clear story: the order book is filling up, but the cash isn't there yet. Annual revenue more than doubled to ₹32.48 crores, a 93% jump from ₹16.87 crores, with Q4 alone delivering ₹16.76 crores. That's the kind of topline growth that explains why the market had already priced in the trend. The problem is profitability. Full-year net profit grew just 39% to ₹54.40 lakhs on that near-tripling of sales. In Q4, a single ₹31 lakh exceptional charge was enough to push the company into a net loss of ₹35.37 lakhs. The board skipped the dividend to keep cash in the business. For a nano-cap contract manufacturer still in the early innings of converting orders into scale, that's the right call. The unmodified audit opinion is a clean bill on the numbers, but the margins are razor-thin, and the next test is whether Veerhealth can convert revenue growth into real profit.

Primary source: BSE · NSE

Veerhealth Care's board meets to approve FY26 results and weigh a dividend

Tipsheet Editorial — Mon, 25 May 2026 15:17:37 GMT

The meeting is routine. The only question is whether the payout lands.

What’s new

Veerhealth Care's board will meet to approve Q4 and FY26 audited results.
The board will also consider recommending a dividend.
The trading window will reopen after the results are public.

Why it matters

This is a procedural notice required by SEBI before a company releases financials. It confirms the upcoming earnings release and puts a dividend on the table, but carries no new information on performance.

What we’re watching

The actual FY26 numbers and dividend amount when released.
Any commentary on profitability or cash flow needed to sustain a payout.
The timeline for results publication after the board meeting.

The full read

Veerhealth Care's board is meeting to approve FY26 audited results and weigh a dividend. This is a procedural notice under SEBI rules. It is a calendar event that precedes every earnings release and contains no new information on the company's financial health or outlook. The trading window for insiders will reopen after the results are public. The only variable is the dividend. Hardly a shock. That depends on the actual FY26 numbers. Not yet.

Primary source: BSE · NSE